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Examining Treatment Decision-Making Among Patients 
With Axial Spondyloarthritis: Insights From a Conjoint 
Analysis Survey
Woojin Joo,1 Christopher V. Almario,2  Mariko Ishimori,2 Yujin Park,3 Alma Jusufagic,1 Benjamin Noah,1  
Lianne S. Gensler,4 R. Swamy Venuturupalli,2  Jonathan Kay,5  Michael H. Weisman,2 and Brennan M.R. Spiegel2
Objective. The number of therapies for axial spondyloarthritis (axSpA) is increasing. Thus, it has become more 
challenging for patients and physicians to navigate the risk-benefit profiles of the various treatment options. In this 
study, we used conjoint analysis—a form of trade-off analysis that elucidates how people make complex decisions 
by balancing competing factors—to examine patient decision-making surrounding medication options for axSpA.
Methods. We conducted an adaptive choice-based conjoint analysis survey for patients with axSpA to assess 
the relative importance of medication attributes (eg, chance of symptom improvement, risk of side effects, route 
of administration, etc) in their decision-making. We also performed logistic regression to explore whether patient 
demographics and disease characteristics predicted decision-making.
Results. Overall, 397 patients with axSpA completed the conjoint analysis survey. Patients prioritized medication 
efficacy (importance score 26.8%), cost (26.3%), and route of administration (13.9%) as most important in their 
decision-making. These were followed by risk of lymphoma (9.5%), dosing frequency (7.2%), risk of serious infection 
(6.0%), tolerability of side effects (5.3%), and clinic visit and laboratory test frequency (4.8%). In regression analyses, 
there were few significant associations between patients’ treatment preferences and sociodemographic and axSpA 
characteristics.
Conclusions. Treatment decision-making in axSpA is highly individualized, and demographics and baseline 
disease characteristics are poor predictors of individual preferences. This calls for the development of online shared 
decision-making tools for patients and providers, with the goal of selecting a treatment that is consistent with patients’ 
preferences.
INTRODUCTION
Axial spondyloarthritis (axSpA) is a chronic, progressive form 
of inflammatory arthritis affecting the axial skeleton and includes 
both nonradiographic axSpA and ankylosing spondylitis (AS) (radi-
ographic form of axSpA) (1,2). There are numerous treatments 
for axSpA, ranging from nonsteroidal anti-inflammatory drugs 
(NSAIDs) to biologics (3-7), and it can be difficult for patients to 
navigate the array of options and choose a therapy that aligns 
with their preferences. Adding to this complexity is that even 
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within medication classes, particularly for biologics, there are vary-
ing mechanisms of action, modes of administration, effectiveness, 
and side effects.
We thus sought to understand how patients with axSpA 
decide from among the different treatment options by using con-
joint analysis—a technique that determines how people make 
complex decisions by balancing competing factors. Conjoint anal-
ysis is based on the idea that any product (eg, a service, test, or 
treatment) can be described by its attributes and is valued based 
on the levels of these attributes. It is administered via a comput-
er-based interactive exercise in which respondents evaluate com-
peting profiles (eg, of axSpA treatments) and select their preferred 
profile (see example in Figure 1). In this study, we specifically aimed 
to quantify and rank-order the relative importance of axSpA med-
ication attributes (eg, efficacy, side effects, route of administration, 
cost, etc) in patients’ decision-making, without making reference 
to any generic or branded products. Furthermore, we evaluated 
whether certain patient factors (ie, sociodemographic and axSpA 
characteristics) predicted preference patterns.
PATIENTS AND METHODS
Overview of conjoint analysis
Conjoint analysis is a method that quantifies how respond-
ents make trade-offs when considering competing factors (8). 
This approach assumes that decision-making is based on the 
attributes of a product, each of which has multiple levels. A series 
of side-by-side profiles of unbranded hypothetical products are 
presented, with each profile having unique levels assigned to each 
attribute (Figure 1). Based on the respondent’s answer to the first 
comparison, an algorithm selects a new side-by-side comparison 
and asks the respondent to select the preferred profile. Conjoint 
analysis is used extensively in clinical research (8), and examples 
extend across diverse domains, including rheumatology (9-11), 
spinal surgery (12), diabetes management (13), and inflammatory 
bowel disease (IBD) (14).
Adaptive choice-based conjoint analysis for  
therapy decision-making in axSpA
We employed adaptive choice-based conjoint (ACBC) analy-
sis software (Sawtooth Software) to determine how patients with 
axSpA make decisions when selecting from among the various 
treatment options. Table 1 displays the eight attributes and their 
associated levels that were tested in the ACBC analysis sur-
vey; these were based on characteristics of axSpA therapies, 
including NSAIDs and biologics. The eight attributes were fur-
ther organized in four categories: 1) medication characteristics 
(route of administration, dosing frequency, frequency of clinic 
appointments, and laboratory testing), 2) efficacy (ie, chance 
of improvement in axSpA symptoms), 3) side effect profile 
Figure 1. Sample choice tournament task in which participants consider three hypothetical medication profiles side by side and decide which 
medication they would prefer for treating their axial spondyloarthritis. Respondents were shown 20 different vignettes, each of which with 
varying attribute levels. Abbreviation: AS, ankylosing spondylitis; IV, intravenous.
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(tolerability of unwanted side effects or reactions, risk of lym-
phoma, and risk of serious infection), and 4) out-of-pocket costs 
per month. These attributes were selected based on input from 
the literature (10,15-18); our axSpA social media netnography 
research, which examined patient concerns and perceptions 
regarding biologics (19); axSpA content experts on the research 
team; and on US Food and Drug Administration labels (includ-
ing “black box warnings”) for currently marketed products to 
ensure accurate representation of factors important in the deci-
sion-making process.
The ACBC analysis software uses the inputted attributes and 
levels to create a series of side-by-side profiles of hypothetical 
axSpA therapies as part of a “choice tournament” with 20 distinct 
decisions (Figure 1). After participants complete the survey, the 
software uses hierarchical Bayes regression to estimate individu-
al-level utility coefficients (20,21). These coefficients—called part-
worth utilities—are generated for each attribute level, and levels 
with greater importance in the decision-making process have 
higher part-worth utilities. The ACBC analysis software also gen-
erates importance scores, which are derived by calculating the Δ 
between the part-worth utilities for the most important and least 
important levels of each attribute (21). A larger Δ in part-worth 
utilities correlates with a larger importance of the attribute in the 
decision-making process. More information about ACBC analysis, 
part-worth utilities, and importance scores (14) can be found at 
the following link: http://links.lww.com/AJG/A215.
Survey design
Prior to the full launch of the survey, the entire instrument 
was pilot tested with five patients with axSpA to ensure under-
standability and usability. Once respondents accessed the sur-
vey, we first assessed their eligibility (see Participants section for 
details). Eligible participants then proceeded through the choice 
tournament exercise as described earlier. Before seeing the first 
set of side-by-side profiles, participants were shown descriptions 
of the medication attributes used in the survey to facilitate their 
understanding of each characteristic (Supplementary Figure 1). 
This information was also available during the choice tournament 
exercise when participants hovered their cursor over the attribute 
labels.
After the conjoint vignettes, the survey presented questions 
regarding sociodemographic information (eg, age, sex, insurance, 
etc) and axSpA characteristics, including time since axSpA symp-
toms started, symptom severity within the past week as meas-
ured by the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) (22), and current and prior axSpA treatments. These 
data were collected to explore potential correlations between 
patient factors and therapy preferences. This study was approved 
at all sites using the Streamlined, Multisite, Accelerated Resources 
for Trials Institutional Review Board (SMART IRB) Reliance plat-
form, with the Cedars-Sinai Institutional Review Board serving as 
the main site (Pro50046).
Table 1. Medication attributes and levels included in the conjoint analysis survey
Attribute Category Specific Attribute Attribute Levels
Medication characteristics Route of administration • Pill by mouth
• Subcutaneous injections at home
• Intravenous infusions in the clinic
• Intravenous infusions at home
 Dosing frequency • Every day
• Every week
• Every 2 wk
• Every 4 wk
• Every 6 wk
 Frequency of clinic appointments and 
laboratory tests
• Every 3 mo
• Every 6 mo
• Every 12 mo




Side effect profile Tolerability of unwanted side effects (ie, 
chance of stopping the medication 




 Risk of lymphomaa •	 2	of	10 000
•	 4	of	10 000
•	 6	of	10 000
 Risk of serious infection • 1%
• 3%
• 5%




Abbreviation: AS, ankylosing spondylitis.
a Respondents were informed that the baseline risk of lymphoma without biologics is 2 of 10 000. 
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Participants
Participants aged 18 years and older with axSpA were 
recruited to complete the online survey between March 14, 2018, 
and June 21, 2019. We recruited patients with axSpA receiving 
care at Cedars-Sinai Medical Center, University of Massachusetts 
(UMass) Memorial Medical Center, and University of California, 
San Francisco (UCSF) Medical Center. We also partnered with 
the Spondylitis Association of America (SAA), who included the 
survey invitation in their June 2018 eSUN newsletter to more than 
25 000 recipients as well as posted the survey link on their web-
site’s “Participate in Spondylitis Research” page. No honorarium 
was awarded to respondents from the above panels for com-
pleting the survey. Participants also needed to confirm that they 
had axSpA by answering “yes” to the question “Have you been 
diagnosed with AS by a physician?” Although we asked about AS 
diagnosis in the survey, we use the axSpA umbrella term through-
out this article because we did not have access to radiographs 




Patients With Medically 
Confirmed axSpAa (n = 122)
Age, mean (SD), y 44.4 (15.7) 51.1 (14.3)
Male sex, % 49.4 68.0
Race/ethnicity, %   
Non-Hispanic white 78.8 70.5
Non-Hispanic black, Latino, non-Hispanic Asian, or other 21.2 29.5
Education, %   
High school or less 10.8 5.7
Some college 19.9 12.3
College degree 34.3 35.3
Graduate degree 35.0 46.7
Married or long-term relationship, % 74.3 68.9
Employed or full-time student, % 68.3 69.7





Prefer not to say 7.8 13.9
Has insurance, % 97.5 100.0
Physical activity vs. others, %   
Much less active 14.1 3.3
Less active 19.9 14.8
Similar 27.0 30.3
More active 23.9 32.0
Much more active 15.1 19.7
Duration of axSpA symptoms, mean (SD), y 16.4 (14.6) 26.6 (14.5)
BASDAI score,b mean (SD) 4.7 (2.3) 3.4 (2.3)
Nonbiologic medication use, %   
Nonselective NSAID 47.6 36.9






Biologic medication exposure, %   
Biologic naïve 30.0 21.3
Prior use of biologics 11.1 10.7
Currently using biologics 58.9 68.0
Recruitment source, %   
Cedars-Sinai Medical Center 15.1 49.2
UMass Memorial Medical Center 3.0 9.8
UCSF Medical Center 12.6 41.0
Spondylitis Association of America 27.5 …
Cint	(survey	research	firm) 41.8 …
Abbreviation: axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
NSAID, nonsteroidal anti-inflammatory drug; UCSF, University of California, San Francisco; UMass, University of 
Massachusetts.
a Patients receiving care at Cedars-Sinai Medical Center, UMass Memorial Medical Center, or UCSF Medical Center. 
b Higher BASDAI score corresponds to more severe symptoms. 
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from those recruited through the SAA or Cint (see details below) 
for distinguishing between AS and nonradiographic axSpA.
We also recruited patients in partnership with Cint, a US 
survey research firm. Because users who complete studies 
through Cint were provided an honorarium, the Cint version of 
the survey included a blinded screening question. Respond-
ents were asked if they had been diagnosed with any of the 
following conditions (presented in random order) by a physi-
cian: AS, juvenile idiopathic arthritis, lupus, osteoarthritis, poly-
myalgia rheumatica, rheumatoid arthritis, or none of the above. 
Only those who stated that they were diagnosed with AS were 
allowed to proceed. By using a screener with six rheumato-
logic conditions, we hoped to maximize the likelihood that 
respondents had been diagnosed with axSpA and were not 
simply seeking compensation by participating in a survey. Of 
note, we performed sensitivity analyses with and without the 
SAA and Cint cohorts to confirm lack of systematic differences 
between self-reported (ie, those from SAA and Cint) and med-
ically confirmed axSpA (ie, patients from Cedars-Sinai, UMass, 
and UCSF medical centers).
Statistical analyses
Based on conjoint analysis sample size precedents and 
recommendations from the software provider (23), we aimed to 
recruit at least 300 patients with axSpA to complete the conjoint 
analysis survey. Statistical analyses were performed using Stata 
13.1 (StataCorp LP). A two-tailed P value of less than 0.05 was 
considered significant. Descriptive analyses were used for patient 
sociodemographic and disease characteristics, importance 
scores, and patient-level preferences report ratings.
We used multivariable logistic regression models to 
adjust for potentially confounding factors and to calculate 
odds ratios and 95% confidence intervals (CIs). The outcomes 
in the models were whether individuals reported the following 
attribute categories as the most important factor in their deci-
sion-making: 1) medication characteristics (route of adminis-
tration, dosing frequency, frequency of clinic appointments), 
2) efficacy, 3) side effect profile (tolerability of unwanted side 
effects or reactions, risk of lymphoma, risk of serious infec-
tion), and 4) cost. The regressions included patient-level 




Supplementary Figure 2 displays the flow diagram of enrolled 
patients, stratified by recruitment source. Demographic and dis-
ease characteristics of the 397 patients with axSpA included in 
the final analysis are presented in Table 2.
Figure 2. Average attribute importance scores for patients with axial spondyloarthritis (N = 397). The mean importance of each medication 
attribute is based on part-worth utilities. Chance of symptom improvement, cost, and route of administration were the most important factors 
and accounted for 26.8%, 26.3%, and 13.9% of decision-making, respectively.
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Overall rank-ordering of medication attribute 
importance
The average importance scores calculated and ranked by 
the ACBC analysis algorithm are shown in Figure 2. On average, 
patients prioritized medication efficacy, cost, and route of admin-
istration as the three most important factors when selecting from 
among the various options. These were followed by risk of lym-
phoma, dosing frequency, risk of serious infection, tolerability of 
side effects, and clinic visit and laboratory test frequency.
When grouping the eight attributes into four overarching cate-
gories, 177 (44.6%) respondents reported efficacy to be the most 
important factor when choosing from among the options. One 
hundred fifty-two (38.3%) and 56 (14.1%) participants reported 
cost and medication characteristics (route of administration, dosing 
frequency, clinic visit and laboratory test frequency), respectively, 
as the predominant factor. Conversely, only 12 (3.0%) prioritized 
side effect profile (tolerability of unwanted side effects or reactions, 
risk of lymphoma, risk of serious infection) in their decision-making.
Route of administration: oral versus subcutane-
ous versus intravenous
In the part-worth utilities assessment, we found that 198 
(49.9%) participants preferred an oral axSpA medication. The 
remaining respondents desired a parenterally delivered medica-
tion. One hundred twenty-eight (32.2%) participants preferred 
subcutaneous administration, whereas 71 (17.9%) participants 
selected an intravenous-infused medication.
Uniqueness of individual preferences report
The conjoint software rank-ordered the relative importance 
scores of all eight medication attributes for each respondent, 
which, taken together, represents an individual preferences report. 
For example, a participant may have the following medication 
attribute rank order: 1) cost, 2) efficacy, 3) route of administra-
tion…8) risk of serious infection. When comparing the reports 
among participants, we found a high level of uniqueness. Figure 3 
shows the proportion of unique decision-making profiles stratified 
by the number of included attributes. When evaluating the rank 
order of all eight attributes, nearly three-quarters of respondents 
had a ranking that did not match that of anyone else. Even when 
limiting the analysis to only four attributes, approximately one-third 
of participants still had a unique report.
Predictors of therapy decision-making
Results from the multivariable regressions assessing inde-
pendent predictors of patient preferences are listed in Table 3. 
Figure 3. Proportion of unique decision-making profiles stratified by number of included attributes (N = 397). For each respondent, the 
conjoint software rank-ordered the importance of the eight medication attributes as he or she selected among the various options. When 
considering individuals’ top three attributes, only 10.8% of respondents had a unique decision-making profile (ie, rank-ordering of top three 
attributes did not match anyone else’s). However, when including all eight medication attributes, 71.5% had unique profiles.
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Overall, sociodemographic and clinical factors largely did not pre-
dict treatment preferences, save for a few exceptions. Individuals 
from high-income households (ie, greater than or equal to 
$200 001 per year) had significantly higher odds of noting med-
ication efficacy as the most important factor when selecting 
from among the options and were less likely to prioritize cost 
or medication characteristics. Increasing duration of axSpA 
symptoms was associated with increased odds for valuing med-
ication efficacy. We also found that increasing levels of physical 
activity was inversely associated with the odds for prioritiz-
ing medication cost. Moreover, those who reported being more 
or similarly active as compared with others had higher odds for 
prioritizing medication efficacy when compared with those who 
were much less active. The remaining variables largely were not 
predictive of decision-making.
Subgroup analyses
We performed a subgroup analysis among the 122 patients 
with axSpA receiving care at Cedars-Sinai, UMass, or UCSF 
(Table 2). When compared against the primary analyses, the over-
all rank-ordering of medication attribute importance was similar: 
Table 3. ORs for reporting medication efficacy, cost, or characteristics as the most important factor in the decision-making process 
(N = 397)a
Variable
Most Important Medication Attribute
Efficacy Cost Medication Characteristicsb
n (%)c OR (95% CI)d n (%)c OR (95% CI)d n (%)c OR (95% CI)d
Age, y … 0.99 (0.97-1.01) … 1.02 (0.99-1.04) … 0.99 (0.96-1.02)
Sex       
Male 90 (45.9) Reference 71 (36.2) Reference 32 (16.3) Reference
Female 87 (43.3) 1.11 (0.70-1.75) 81 (40.3) 0.99 (0.62-1.56) 24 (11.9) 0.66 (0.35-1.25)
Race/ethnicity       
Non-Hispanic white 136 (43.5) Reference 130 (41.5) Reference 37 (11.8) Reference
Non-Hispanic black, Latino,  
non-Hispanic Asian, or other
41 (48.8) 1.12 (0.63-1.97) 22 (26.2) 0.58 (0.32-1.06) 19 (22.6) 1.96 (0.96-4.00)
Education       
High school or less 16 (37.2) Reference 17 (39.5) Reference 9 (20.9) Reference
Some college 34 (43.0) 1.13 (0.49-2.56) 32 (40.5) 1.05 (0.46-2.39) 11 (13.9) 0.75 (0.26-2.16)
College degree 53 (39.0) 0.78 (0.35-1.73) 63 (46.3) 1.66 (0.75-3.66) 16 (11.8) 0.59 (0.21-1.61)
Graduate degree 74 (53.2) 1.11 (0.49-2.52) 40 (28.8) 0.90 (0.39-2.08) 20 (14.4) 0.84 (0.29-2.37)
Relationship status       
Married or long-term relationship 130 (44.1) Reference 113 (38.3) Reference 44 (14.9) Reference
Not married 47 (46.1) 1.26 (0.73-2.20) 39 (38.2) 0.85 (0.48-1.51) 12 (11.8) 0.81 (0.37-1.80)
Employment status       
Unemployed 56 (44.4) Reference 48 (38.1) Reference 18 (14.3) Reference
Employed or student 121 (44.7) 0.83 (0.47-1.47) 104 (38.4) 1.56 (0.86-2.82) 38 (14.0) 0.59 (0.26-1.32)
Total household income       
≤$50 000 33 (37.5) Reference 41 (46.6) reference 13 (14.8) Reference
$50 001-$100 000 37 (37.4) 0.95 (0.48-1.88) 45 (45.5) 1.03 (0.52-2.02) 13 (13.1) 0.73 (0.28-1.89)
$100 001-$200 000 43 (35.0) 0.97 (0.47-1.99) 51 (41.5) 0.75 (0.36-1.55) 25 (20.3) 1.28 (0.49-3.33)
≥$200 001 44 (78.6) 6.38 (2.51-16.22) 10 (17.9) 0.27 (0.10-0.71) 2 (3.6) 0.14 (0.03-0.76)
Prefer not to say 20 (64.5) 2.72 (1.08-6.87) 5 (16.1) 0.26 (0.09-0.80) 3 (9.7) 0.45 (0.11-1.94)
Physical activity vs. others       
Much less active 15 (26.8) Reference 34 (60.7) Reference 4 (7.1) Reference
Less active 33 (41.8) 2.15 (0.95-4.88) 30 (38.0) 0.39 (0.18-0.84) 11 (13.9) 1.81 (0.51-6.49)
Similar 53 (49.5) 2.70 (1.22-5.96) 38 (35.5) 0.38 (0.18-0.80) 15 (14.0) 2.11 (0.61-7.25)
More active 50 (52.6) 2.39 (1.04-5.52) 30 (31.6) 0.40 (0.18-0.89) 14 (14.7) 2.45 (0.68-8.78)
Much more active 26 (43.3) 1.47 (0.59-3.62) 20 (33.3) 0.51 (0.22-1.21) 12 (20.0) 3.37 (0.89-12.79)
Duration of axSpA symptoms, y … 1.030 (1.009-1.052) … 0.978 (0.957-0.999) … 0.988 (0.958-1.018)
BASDAI score … 0.99 (0.88-1.10) … 1.07 (0.95-1.20) … 0.94 (0.81-1.10)
Biologic medication use       
Biologic naïve 46 (38.7) Reference 51 (42.9) Reference 17 (14.3) Reference
Prior use of biologics 17 (38.7) 1.04 (0.48-2.27) 22 (50.0) 1.34 (0.62-2.89) 5 (11.4) 0.73 (0.23-2.32)
Currently using biologics 114 (48.7) 1.49 (0.87-2.56) 79 (33.8) 0.71 (0.41-1.23) 34 (14.5) 0.94 (0.44-1.97)
Abbreviation: axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CI, confidence interval; OR, odds ratio.
a We did not conduct a regression on reporting of the side effect profile as the most important factor in the decision-making process because 
only 12 individuals prioritized it in the study. 
b Includes route of administration, dosing frequency, and clinic visit and laboratory test frequency. 
c Represents the number of persons prioritizing the respective factor as the most important in their decision-making process. 
d The multivariable logistic regression model included all covariates in the table. Insurance status was not included in the model because 97.5% 
of respondents had health insurance. 
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symptom improvement, 32.3%; cost, 23.8%; route of admin-
istration, 14.9%; risk of lymphoma, 9.8%; risk of serious infec-
tion, 5.5%; dosing frequency, 5.3%; tolerability of unwanted side 
effects, 4.5%; clinic visit and laboratory test frequency, 3.9%. We 
also continued to see a high level of uniqueness with respect to 
respondents’ preferences report; when considering their rankings 
of the eight attributes, we found that 90 (73.8%) participants had 
a report that did not match anyone else’s.
When grouping the eight attributes into four overarching 
categories, we found that participants prioritized the following 
as the most important factor in their decision-making: efficacy 
(76 [62.3%]), cost (28 [23.0%]), medication characteristics (16 
[13.1%]), and side effect profile (2 [1.6%]). Similar to the primary 
regression analyses, patient sociodemographic and axSpA char-
acteristics largely were not predictive of decision-making (Sup-
plementary Table 1). The one exception was income; those from 
households making greater than or equal to $200 001 per year 
had 8.34 (95% CI 1.24-56.11) times the odds of prioritizing medi-
cation efficacy compared with those making less than or equal to 
$50 000 per year.
DISCUSSION
Using conjoint analysis, we found that on average, patients 
with axSpA prioritize medication efficacy, cost, and route of 
administration when selecting from among the various options. 
However, we also found that treatment decision-making is highly 
individualized; patient sociodemographic and axSpA clinical char-
acteristics poorly predict medication preferences.
Our analysis is one of a small number of studies that have 
analyzed how patients with axSpA make decisions regarding 
potential therapies. Nolla et al (10) conducted a conjoint analysis 
assessing attribute preferences of biologics used in the treatment 
of rheumatologic diseases in Spain. Among patients with axSpA, 
the authors found that patients prioritize pain relief, followed by 
risk of adverse events (high vs. low risk), administration method, 
and, lastly, duration of effects. Conversely, our study—which also 
included costs and specific side effects and modeled both bio-
logic and nonbiologic options—found that patients value symptom 
improvement the most, followed by cost, route of administration, 
and risk of lymphoma.
To our knowledge, our study is the first to assess the impact 
of medication out-of-pocket costs on decision-making in axSpA, 
which ranks second highest in importance among patients. Not 
surprisingly, household income influences how cost is factored 
into decision-making. Individuals reporting a household income of 
less than or equal to $50 000 are more likely to prioritize cost com-
pared with those from households making more than $200 000. 
Of note, prior studies in rheumatoid arthritis have assessed the 
role of medication costs in decision-making (24,25). Augustovski 
et al (24) found that cost is the most important consideration in 
choosing a rheumatoid arthritis medication among Argentini-
ans, whereas Louder et al (25) noted that cost is the fourth most 
important of seven attributes in commercially insured Americans. 
Additional research examining how medication costs impact 
treatment decision-making, adherence, and outcomes in axSpA 
is warranted.
Our finding of the highly individualized nature of selecting 
an axSpA treatment is consistent with our prior study examining 
biologic decision-making among patients with IBD (14). However, 
when responses between the cohorts are considered, some dif-
ferences are noted. Although the proportions of individuals with 
axSpA (45%) and IBD (41%) who reported efficacy as the most 
important factor in the decision-making process were similar, a 
higher percentage of patients with IBD (38%) prioritized avoidance 
of side effects compared with those with axSpA (3%) (14). This 
suggests that patients with axSpA may approach treatment deci-
sion-making differently from those with IBD. Of note, the conjoint 
analysis survey administered to those with IBD did not include 
cost, which was highly valued among individuals with axSpA. It 
is possible that the proportion of patients with IBD who prioritized 
avoidance of side effects would have decreased had cost been 
included as an attribute in the survey. Regardless, this calls for 
the need for further research to better understand how those with 
axSpA consider medication side effects when choosing a therapy.
In our analyses, when attempting to identify predictors of 
individual choices, we found that sociodemographic and axSpA 
clinical factors were rarely helpful in predicting medication prefer-
ences, except in a few cases. For example, we found that those 
with total household incomes greater than $200 000 and patients 
with a longer duration of axSpA symptoms were more likely to pri-
oritize efficacy when choosing from among the different treatment 
options. We also discovered that individuals who reported higher 
levels of physical activity as compared with others were less likely 
to note out-of-pocket cost as the most important factor. These 
patients may be willing to spend more money on axSpA thera-
pies to maintain their active lifestyles. Interestingly, axSpA symp-
tom severity, as measured by the BASDAI, is not associated with 
decision-making; worse symptoms do not predict prioritization of 
a medication’s efficacy when choosing an axSpA therapy. Moreo-
ver, when considering each respondent’s preferences report, we 
found that nearly three-quarters had a completely unique deci-
sion-making profile. These results emphasize that providers can-
not rely on demographic or clinical variables to accurately predict 
which therapy will align with a patient’s personal values.
Because of the highly individualized nature of decision-making 
in axSpA, along with health care’s increased emphasis on shared 
decision-making between patients and providers (11,26,27), it is 
important for clinicians to identify what matters most to patients 
when choosing from among therapeutic options. Yet, in the context 
of a brief clinical visit, it can be challenging for rheumatologists to 
determine a patient’s unique preferences profile while also engaging 
in detailed discussions around each treatment’s risks, benefits, and 
trade-offs. Thus, there is a need for simple and efficient decision 
TREATMENT DECISION-MAKING IN axSpA |      9
tools that elicit individual preferences and support the patient-pro-
vider interaction. In IBD, we developed an online decision aid called 
IBD&me (www.ibdan dme.org) that uses conjoint analysis to assess 
a patient’s priorities when selecting a biologic medicine and then 
generates a personalized report that displays the rank order of 
attributes that matter most to an individual (14). The patient can 
share the report with his or her physician, who can review the infor-
mation to quickly understand the patient’s preferences.
Our study has limitations. First, we only recruited subjects 
from the United States; our findings may not be generalizable to 
patients with axSpA in other parts of the world. As many inter-
national rheumatology societies stress the importance of shared 
decision-making between patients and providers when choosing 
a treatment (3,7,28), additional studies in other countries examin-
ing axSpA therapy decision-making are warranted. Second, our 
study included patients with self-reported axSpA. However, in 
sensitivity analyses that only included data from those confirmed 
to have the condition at academic medical centers, the findings 
were largely similar to the primary analyses. Third, we limited the 
study to eight attributes. Patients may have other considerations 
when selecting an axSpA therapy (eg, length of time since drug 
approval, mechanism of action, risk of hepatitis B reactivation, 
etc) that were not included in the survey. However, this was by 
design because ACBC analysis surveys can become unwieldy 
with too many attributes, and we decided to focus on eight core 
attributes that were deliberately chosen based on prior literature 
(15-19,29,30) and input from content experts to capture the most 
important considerations patients weigh when selecting a therapy. 
Fourth, our conjoint analysis included medication profiles mod-
eled after oral (ie, NSAIDs) as well as parenteral (ie, biologics) 
therapies. It is possible that patients’ decision-making would 
have differed had the survey only included biologic options; this 
is worthy of further study, particularly among patients with axSpA 
who remain symptomatic despite NSAIDs and are considering 
biologics. Fifth, despite the interactive design of the survey and 
limitation to 20 conjoint vignettes, patients may have found the 
serial decision-making challenging. Similarly, patients with lower 
numeracy skills may have experienced difficulty interpreting the 
risks provided. It can be argued, however, that this exercise is at 
least comparable to clinic-based decision-making for determining 
patient preferences because patients may complete the survey at 
their own pace while carefully considering trade-offs.
In conclusion, we found that patients with axSpA highly 
value medication efficacy, cost, and route of administration when 
selecting from among the various therapeutic options. We also 
discovered that the decision-making process is highly individual-
ized because sociodemographic and clinical characteristics poorly 
predict preferences. With the increasing number of therapeutic 
options becoming available for patients, these results underscore 
the need for development of treatment decision tools to enhance 
communication and shared decision-making between patients 
and providers. This will optimize selection of therapies that match 
patients’ unique preferences and may ultimately improve medica-
tion adherence and outcomes.
ACKNOWLEDGMENTS
We would like to thank and acknowledge Elin Aslanyan at the 
SAA for her support in our recruitment efforts.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revis-
ing it critically for important intellectual content, and all authors 
approved the final version to be published. Dr. Almario had full 
access to all of the data in the study and takes responsibility for 
the integrity of the data and the accuracy of the data analysis.
Study conception and design. Joo, Almario, Ishimori, Park, Noah, 
Weisman, Spiegel.
Acquisition of data. Joo, Almario, Ishimori, Jusufagic, Noah, Gensler, 
Venuturupalli, Kay, Spiegel.
Analysis and interpretation of data. Joo, Almario, Ishimori, Park, 
Jusufagic, Gensler, Venuturupalli, Kay, Weisman, Spiegel.
ROLE OF THE STUDY SPONSOR
Novartis Pharmaceuticals Corporation had no role in the study 
design or in the collection, analysis, or interpretation of the data, 
the writing of the manuscript, or the decision to submit the manu-
script for publication. Publication of this article was not contingent 
upon approval by Novartis Pharmaceuticals Corporation.
REFERENCES
 1. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial 
spondyloarthritis. N Engl J Med 2016;374:2563–74.
 2. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spon-
dylitis: an overview. Ann Rheum Dis 2002;61 Suppl 3:iii8–18.
 3. Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, 
et al. American College of Rheumatology/Spondylitis Association 
of America/Spondyloarthritis Research and Treatment Network 
2015 recommendations for the treatment of ankylosing spondyli-
tis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 
2016;68:282–98.
 4. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. 
Cochrane Database Syst Rev 2014:CD004800.
 5. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spon-
dylitis. Cochrane Database Syst Rev 2013:CD004524.
 6. Van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck 
YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, ran-
domised, placebo controlled study of leflunomide in the treat-
ment of active ankylosing spondylitis. Ann Rheum Dis 2005;64: 
1761–4.
 7. Van der Heijde D, Ramiro S, Landewe R, Baraliakos X, van den 
Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR man-
agement recommendations for axial spondyloarthritis. Ann Rheum 
Dis 2017;76:978–91.
 8. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, 
et al. Conjoint analysis applications in health: a checklist: a report 
of the ISPOR Good Research Practices for Conjoint Analysis Task 
Force. Value Health 2011;14:403–13.
 9. Kievit W, van Hulst L, van Riel P, Fraenkel L. Factors that influence 
rheumatologists’ decisions to escalate care in rheumatoid arthritis: 
JOO ET AL 10       |
results from a choice-based conjoint analysis. Arthritis Care Res 
(Hoboken) 2010;62:842–7.
 10. Nolla JM, Rodriguez M, Martin-Mola E, Raya E, Ibero I, Nocea G, 
et al. Patients’ and rheumatologists’ preferences for the attributes 
of biological agents used in the treatment of rheumatic diseases in 
Spain. Patient Prefer Adherence 2016;10:1101–13.
 11. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal 
R, et al. The 2010 American College of Rheumatology/European 
League Against Rheumatism classification criteria for rheumatoid 
arthritis: phase 2 methodological report. Arthritis Rheum 2010;62: 
2582–91.
 12. Bederman SS, Mahomed NN, Kreder HJ, McIsaac WJ, Coyte PC, 
Wright JG. In the eye of the beholder: preferences of patients, family 
physicians, and surgeons for lumbar spinal surgery. Spine (Phila Pa 
1976) 2010;35:108–115.
 13. Porzsolt F, Clouth J, Deutschmann M, Hippler HJ. Preferences of 
diabetes patients and physicians: a feasibility study to identify the 
key indicators for appraisal of health care values. Health Qual Life 
Outcomes 2010;8:125.
 14. Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, 
et al. Optimizing selection of biologics in inflammatory bowel dis-
ease: development of an online patient decision aid using conjoint 
analysis. Am J Gastroenterol 2018;113:58–71.
 15. Bolge SC, Eldridge HM, Lofland JH, Ravin C, Hart PJ, Ingham MP. 
Patient experience with intravenous biologic therapies for ankylos-
ing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheu-
matoid arthritis, and ulcerative colitis. Patient Prefer Adherence 
2017;11:661–9.
 16. Cinar FI, Cinar M, Yilmaz S, Simsek I, Erdem H, Pay S. Thoughts and 
perceptions of ankylosing spondylitis patients with regard to TNF 
inhibitors. Rheumatol Int 2014;34:979–86.
 17. Fajri DW, Brand CA, Dharmage SC, Martin BJ, Buchanan RR, 
Schachna L. What factors determine patients’ preference for tumour 
necrosis factor inhibitors in ankylosing spondylitis? [Brief Report]. 
Clin Rheumatol 2009;28:599–602.
 18. Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli 
R, Lapadula G, et al. Patients’, physicians’, nurses’, and pharma-
cists’ preferences on the characteristics of biologic agents used 
in the treatment of rheumatic diseases. Patient Prefer Adherence 
2018;12:2153–68.
 19. Dzubur E, Khalil C, Almario CV, Noah B, Minhas D, Ishimori M, et al. 
Patients’ concerns and perceptions regarding biologic therapies in 
ankylosing spondylitis: insights from a large-scale survey of social 
media platforms. Arthritis Care Res (Hoboken) 2019;71:323–30.
 20. Cunningham CE, Deal K, Chen Y. Adaptive choice-based conjoint 
analysis: a new patient-centered approach to the assessment of 
health service preferences. Patient 2010;3:257–73.
 21. Lichtenstein GR, Waters HC, Kelly J, McDonald SS, Zanutto EL, 
Hendricks D, et al. Assessing drug treatment preferences of patients 
with Crohn’s disease: a conjoint analysis. Patient 2010;3:113–23.
 22. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin 
A. A new approach to defining disease status in ankylosing spondy-
litis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheu-
matol 1994;21:2286–91.
 23. Orme BK. Getting started with conjoint analysis: strategies for prod-
uct design and pricing research. 2nd ed. Madison (WI): Research 
Publishers; 2010.
 24. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, 
Gonzalez J, et al. Patient preferences for biologic agents in rheuma-
toid arthritis: a discrete-choice experiment. Value Health 2013;16: 
385–93.
 25. Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, 
et al. Patient preferences regarding rheumatoid arthritis therapies: a 
conjoint analysis. Am Health Drug Benefits 2016;9:84–93.
 26. Oshima Lee E, Emanuel EJ. Shared decision making to improve care 
and reduce costs. N Engl J Med 2013;368:6–8.
 27. Siegel CA. Shared decision making in inflammatory bowel disease: 
helping patients understand the tradeoffs between treatment op-
tions. Gut 2012;61:459–65.
 28. Wei JC, Liu CH, Tseng JC, Hsieh LF, Chen CH, Chen HH, et al. 
Taiwan Rheumatology Association consensus recommendations for 
the management of axial spondyloarthritis. Int J Rheum Dis 2020;23: 
7–23.
 29. Stockdale J, Goodacre L. ’It’s magic stuff’: the experiences of pa-
tients with ankylosing spondylitis taking anti-TNF-α medication. 
Musculoskeletal Care 2009;7:162–77.
 30. Madsen M, Jensen KV, Esbensen BA. Men’s experiences of living 
with ankylosing spondylitis: a qualitative study. Musculoskeletal Care 
2015;13:31–41.
